Evidence map›Paper›PMID 40607207›Full record

ArticleKidney medicine2025

RECOVID: Retrospective Observational Study of Renal Outcomes and Long-Term Mortality in Patients With COVID-19-Associated AKI, A Comparison Between Vaccinated and Unvaccinated Patients.

Niloofar Nobakht, Charley Jang, Tristan Grogan, Peter Fahim, Ira Kurtz, Joanna Schaenman, James Wilson, Mohammad Kamgar, RECOVID Investigators

Abstract read
In one paragraph

Article in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Niloofar NobakhtDivision of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, LA.
Charley JangDivision of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, LA.
Tristan GroganDepartment of Medicine Statistics Core, Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, LA.
Peter FahimDivision of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, LA.
Ira KurtzDivision of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, LA.
Joanna SchaenmanDivision of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, LA.
James WilsonDivision of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, LA.
Mohammad KamgarDivision of Nephrology, Department of Medicine, David Geffen School of Medicine at UCLA, University of California Los Angeles, LA.
RECOVID Investigators

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale & Objective: Acute kidney injury (AKI) is a common complication in patients with Coronavirus disease-2019 (COVID-19) infections, with rates as high as 32% to 46%, and it has been associated with poor outcomes. However, the long-term renal and survival outcomes among hospitalized patients with COVID-19 and AKI are not fully understood. Study Design: A single-center cohort study. Setting & Participants: Total of 972 adult patients admitted with COVID-19 infection and AKI at a single large urban academic medical center from March 1, 2022, to March 30, 2022. Among these, 411 (42.3%) did not receive a dose of a US FDA-approved COVID-19 vaccine, and 467 (48.0%) had completed the primary vaccine series. Exposure: Patients admitted with COVID-19 infection and AKI were analyzed using vaccination status as the exposure. Additional exposures included demographics, comorbid conditions, and need for continuous renal replacement therapy (CRRT) during hospitalization. Outcome: The primary outcome was in-hospital mortality. Secondary outcomes included long-term mortality, length of hospital stay, and the need for renal replacement therapy (RRT) at discharge. Analytical Approach: The vaccinated and unvaccinated cohorts were characterized using descriptive analyses. The cohorts were analyzed using the Kaplan-Meier method and groups were compared using the log-rank test. Multivariable cox, logistic, and linear regression models were used for mortality, RRT status at discharge, and length of stay, respectively. Results: Among 3,527 hospitalized patients with a COVID-19 infection, AKI occurred in 972 patients. Of the 972 patients with AKI, 411 (42.3%) did not receive a dose of a US FDA-approved COVID-19 vaccine and 467 (48.0%) had completed the primary vaccine series. Unvaccinated patients had a higher rate of requiring CRRT during their hospitalization compared with vaccinated patients (15.8% vs 10.9%, Limitations: There was a lack of data on the ventilation status and other indicators of infection severity in patients in intensive care unit who received CRRT. In addition, data on booster COVID-19 vaccinations were lacking. Conclusions: Vaccinated patients with a COVID-19 infection and AKI had an increase overall survival and were less likely to remain on RRT at the time of discharge. Further studies evaluating the underlying etiologies of AKI and renal outcomes among patients admitted with COVID-19 infection in both vaccinated and unvaccinated patients is important in the development of targeted therapies and guidance on management and follow-up approaches to monitor renal recovery and model outcomes for providing chronic kidney disease care for these patients.

Indexed as

Acute kidney injuryCOVID-19renal outcomesrenal replacement therapyvaccination

Identifiers

PMID40607207
PMCPMC12221444

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.